Cancer reduction in mice with Prakasine nanomedicine immunotherapy
Source abstract
Abstract
In this study, non-toxic mercury nanoparticle Prakasine (PRK-NP) was synthesized as per 'Prakash theory of metal drugs' and nanoparticle's non toxicity has been demonstrated by employing in vitro MTT (dose 320ug/ml), SBR (dose 80ug/ml) and apoptosis assays (dose 320ug/ml), and in vivo acute and chronic toxicity studies in mice (n 12, dose 900 mg/kg body weight oral), rat (n 14, dose 500 mg/kg body weight oral for 18 months), rabbit (n 14, dose 500 mg/kg body weight oral for 18 months) and dogs (n 14, dose 500 mg/kg body weight oral for 18 months).The MTT, SBR and apoptosis assays established no cytotoxicity, no genotoxicity and no cytolytic anticancer effects.The mice, rat, rabbit and dog studies also indicated nontoxicity.The PRK-NPs significantly reduced the breast cancer tumour in murine mammary tumour -C3H/HeJ model 35% and 43.7% in mice at doses of 200 mg/kg and 500 mg/kg respectively.Also, in xenograft mammary tumour mice model the tumour regressions are 25.7% and 83% in the doses of 500 mg/kg and 1000 mg/kg respectively, compared to standard positive control drugs without any adverse effects and toxicity.Thus, the current study beholds anticipation PRK-NPs may play a vital role in therapeutic.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Immunotherapy and Immune Responses · Nanoparticle-Based Drug Delivery · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Naval AIDS Research Centre, Namakkal, Tamil Nadu, India
References (75)
Show source-provided references
1. Ferlay J Ervik M Lam F et al. Global Cancer Observatory: Cancer Today. Lyon: International Agency for Research on Cancer; 2020 (https://gco.iarc.fr/today. accessed February 2021).
2. World Health Organization. Cancer; 2020. https://www.who.int/news-room/fact-sheets/detail/cancer#:∼:text.
3. 10.1016/S2214-109X(19)30488-710.1016/S2214-109X(19)30488-7 ↗
4. Ren Minghui. Assessing national capacity for the prevention and control of noncommunicable diseases: report of the 2019 global survey. Geneva: World Health Organization; 2020. https://iris.who.int/bitstream/handle/10665/331452/9789240002319-eng.pdf?sequence=1
5. Key Statistics for Breast Cancer. American Cancer Society; 2023. https://www.cancer.org/cancer/types/breast-cancer/about/how-common-is-breast-cancer.html.
6. 10.4137/BCBCR.S2942010.4137/BCBCR.S29420 ↗
7. 10.1002/cncr.3288710.1002/cncr.32887 ↗
8. 10.1002/cncr.2933110.1002/cncr.29331 ↗
9. 10.1016/s0140-6736(99)02143-110.1016/s0140-6736(99)02143-1 ↗
10. 10.1111/j.1582-4934.2005.tb00350.x10.1111/j.1582-4934.2005.tb00350.x ↗
11. 10.1186/s13058-015-0580-510.1186/s13058-015-0580-5 ↗
12. 10.7326/0003-4819-155-8-201110180-0000510.7326/0003-4819-155-8-201110180-00005 ↗
13. 10.1586/era.09.7510.1586/era.09.75 ↗
14. 10.1016/s0002-9610(05)80793-710.1016/s0002-9610(05)80793-7 ↗
15. Kroese M, Zimmern RL, Pinder SE. HER2 status in breast cancer—an example of pharmacogenetic testing. J R Soc Med. 2007;100(7):326–329.
16. 10.1007/978-1-60327-492-0_1310.1007/978-1-60327-492-0_13 ↗
17. 10.3109/10731199.2010.49457810.3109/10731199.2010.494578 ↗
18. 10.1038/s41523-023-00508-310.1038/s41523-023-00508-3 ↗
19. 10.1080/21691401.2023.217321710.1080/21691401.2023.2173217 ↗
20. 10.1007/s00436-011-2387-310.1007/s00436-011-2387-3 ↗
21. 10.1016/j.carbpol.2020.11628210.1016/j.carbpol.2020.116282 ↗
22. 10.1016/j.bioorg.2020.10435710.1016/j.bioorg.2020.104357 ↗
23. 10.1016/j.bioorg.2020.10444710.1016/j.bioorg.2020.104447 ↗
24. 10.1016/0022-1759(93)90011-u10.1016/0022-1759(93)90011-u ↗
25. 10.1016/S0887-2333(01)00014-510.1016/S0887-2333(01)00014-5 ↗
26. 10.1016/s0003-2697(03)00322-110.1016/s0003-2697(03)00322-1 ↗
27. Kangas L, Grönroos M, Nieminen AL, et al. Bioluminescence of cellular ATP: a new method for evaluating cytotoxic agents in vitro. Med Biol. 1984;62(6):338–343.
28. 10.1016/0076-6879(86)33053-210.1016/0076-6879(86)33053-2 ↗
29. Cell viability and proliferation. Mark Frei, BioFiles. 2011; 6(5):17–21.
30. 10.1016/0022-1759(86)90368-610.1016/0022-1759(86)90368-6 ↗
31. 10.1101/pdb.prot449310.1101/pdb.prot4493 ↗
32. 10.12659/MSMBR.89332710.12659/MSMBR.893327 ↗
33. 10.1038/nprot.2006.17910.1038/nprot.2006.179 ↗
34. 10.1093/jnci/82.13.110710.1093/jnci/82.13.1107 ↗
35. 10.36062/ijah.60.1.2021.58-6510.36062/ijah.60.1.2021.58-65 ↗
36. Simona P, Ana-Maria Teodoru NL, Coman C. Hematological and biochemical dynamics of rabbits and guinea pigs used for scientific purposes at Cantacuzino Institute, Bucharest. Rev RomMed Vet. 2021;31, 2:69–80. ISSN:1220-3173; E-ISSN:2457–7618.
37. Poljičak-Milas N, Kardum-Skelin I, Vuđan M, et al. Blood cell count analyses and erythrocyte morphometry in New Zealand white rabbits. Vet. arhiv. 2009;79(6):561–571.
38. 10.5455/OVJ.2011.v1.i0.p1310.5455/OVJ.2011.v1.i0.p13 ↗
39. Lumsden JH, Mullen K, McSherry BJ. Canine hematology and biochemistry reference values. Can J Comp Med. 1979;43(2):125–131. PMID: 497885; PMCID: PMC1319907.
40. 10.1038/s41467-023-36045-710.1038/s41467-023-36045-7 ↗
41. 10.1038/nrc315310.1038/nrc3153 ↗
42. 10.1038/s41577-020-0306-510.1038/s41577-020-0306-5 ↗
43. 10.1038/s41577-019-0210-z10.1038/s41577-019-0210-z ↗
44. 10.1038/s41586-022-05531-110.1038/s41586-022-05531-1 ↗
45. 10.1038/s41586-022-05531-110.1038/s41586-022-05531-1 ↗
46. 10.1038/s41591-018-0014-x10.1038/s41591-018-0014-x ↗
47. 10.1038/nrc158610.1038/nrc1586 ↗
48. 10.1038/s41571-019-0175-710.1038/s41571-019-0175-7 ↗
49. 10.1016/j.ccr.2012.02.02210.1016/j.ccr.2012.02.022 ↗
50. 10.1038/s41467-022-28279-810.1038/s41467-022-28279-8 ↗
51. 10.1038/s43018-023-00542-x10.1038/s43018-023-00542-x ↗
52. 10.1016/j.surg.2019.09.01810.1016/j.surg.2019.09.018 ↗
53. 10.1038/s41467-022-34744-110.1038/s41467-022-34744-1 ↗
54. 10.1056/NEJMoa180961510.1056/NEJMoa1809615 ↗
55. 10.1001/jamaoncol.2018.515210.1001/jamaoncol.2018.5152 ↗
56. 10.1038/s41571-019-0308-z10.1038/s41571-019-0308-z ↗
57. 10.1038/nrclinonc.2010.13910.1038/nrclinonc.2010.139 ↗
58. 10.1016/j.trecan.2018.02.00510.1016/j.trecan.2018.02.005 ↗
59. 10.1146/annurev-physiol-020518-11470010.1146/annurev-physiol-020518-114700 ↗
60. 10.1073/pnas.121335310910.1073/pnas.1213353109 ↗
61. 10.1126/science.aaz086810.1126/science.aaz0868 ↗
62. 10.1016/j.jbiomech.2014.09.01910.1016/j.jbiomech.2014.09.019 ↗
63. 10.3389/fonc.2018.0005510.3389/fonc.2018.00055 ↗
64. 10.1371/journal.pone.019380110.1371/journal.pone.0193801 ↗
65. 10.1158/0008-5472.CAN-12-452110.1158/0008-5472.CAN-12-4521 ↗
66. 10.1016/j.ccr.2014.06.00310.1016/j.ccr.2014.06.003 ↗
67. 10.1126/science.117136210.1126/science.1171362 ↗
68. 10.1038/ncomms.351610.1038/ncomms.3516 ↗
69. 10.1038/d41587-019-00019-210.1038/d41587-019-00019-2 ↗
70. 10.1002/wnan.173010.1002/wnan.1730 ↗
71. 10.1080/21655979.2021.201290710.1080/21655979.2021.2012907 ↗
72. Prakash SK. Effect of feed supplementation of mercury nanoparticles on immunostimulation of live lentogenic Newcastle disease vaccine in layer birds. Indian Vet J. 2017;94:11–13.
73. Prakash SK. Immunological and virological effects of novel prakasine nanomedicine in HIV-infected patients in South India: a preliminary study. Virol Antivir Res. 2020;9(2):195.
74. Prakash SK. Phytochemical therapy as a possible cure for asymptomatic AIDS patients [dissertation]. India: Bharathidasan University; 2010.
75. Prakash SK. Immunological and virological effects of prakasine nanomedicine in HIV eradication: a preliminary study. Fifth Eastern Europe and Central Asia AIDS conference. ; 2016 23–25. Moscow